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Human T cell lymphotrophic Virus 1 (HTLV-1) is endemic in
the Caribbean, parts of South America, West Africa, Asia
and Oceania but rare in North America. After a prolonged
latency, HTLV-1 is associated with development of acute T
cell leukemia/lymphoma (ATL) in 2–5% of infected individ-
uals and HTLV-1-associated myelopathy (HAM) in a smaller
percentage. Screening tests do not distinguish between
HTLV-1 and HTLV-2 (not associated with disease) and most
screen positive patients in nonendemic areas have HTLV-2
or a false positive result.
Before 2009, the Organ Procurement and Transplant Net-
work (OPTN) required HTLV-1 testing on all deceased
donors. Driven partly by the planned discontinuation in
2009 of the only FDA licensed screening assay practical
for Organ Procurement Organization (OPO) use, an analy-
sis of the risk/benefit of HTLV-1 screening was undertaken
(1). This revealed that the prevalence of HTLV-1 infection
was likely very low in potential organ donors (0.03–0.5%).
Despite the use of screen positive organs by selected cen-
ters with good short-term outcomes, most screen positive
donors were not used and 167–227 organs were discarded
annually. However, only 3–27% of these organs were likely
infected with HTLV-1 (1). On the basis of this analysis,
OPTN removed the requirement for universal deceased
donor screening. Concern existed that the data used to
make the above policy change was inadequate and that
a period of retrospective testing would allow better deter-
mination of the true prevalence of HTLV-1 in organ donors,
the risk of transmission and the expected natural history of
donor-derived HTLV-1 infection. Largely because of practi-
cal concerns regarding retrospective testing, this proposal
was not adopted.
The policy decision to discontinue universal donor HTLV-1
screening was not driven by the assumption that donor
derived HTLV-1 infection will never occur; only that given
poor performance of the test in a low seroprevalence pop-
ulations, the risk benefit calculation did not favor contin-
ued testing. Thus, questions regarding HTLV-1 infection in
solid organ transplantation (SOT) remain important (per-
haps even more so in the absence of universal testing).
Specifically, the three leading issues include understanding
the risk of donor derived HTLV-1 disease, the natural history
of HTLV-1 after SOT in a patient with pretransplant infec-
tion and the appropriate monitoring of infected/potentially
infected recipients. In series that include long term follow
up, few pretransplant HTLV-1 positive kidney transplant re-
cipients develop ATL/HAM (2). Nonetheless, one series
looking at cases of posttransplant lymphoproliferative dis-
order (PTLD) noted that 5 of 24 cases in kidney recipients
were ATL in HTLV-1 positive patients suggesting that at
least in some cases immunosuppression may hasten the
development of HTLV-1 associated disease (3). Regarding
donor derived HTLV-1 (a situation that might be higher risk
than a positive recipient with some pretransplant immune
response), one case report describes the relatively rapid
development of HAM in three recipients of one HTLV-1
infected donor (4). Other reports describe possible donor
derived HTLV-1 disease as well as asymptomatic probable
donor derived infection.
The current report by Yoshizumi et al. (from an endemic
area in Japan) provides some additional information regard-
ing all of the above questions and raises additional concern
regarding the risk of the development of serious HTLV-
1 disease in seropositive recipients (5). Combined with
their previous report, this series represents the only report
describing the natural history of HTLV-1 after liver transplan-
tation. Over a 14 year period, 26/329 living donor liver trans-
plants (LDLT) were performed on HTLV-1 positive recipi-
ents. Standard maintenance immunosuppression without
cell-depleting induction and tapering to calcineurin inhibitor
alone at 6 months was used. Fifteen percent (4/26) devel-
oped ATL (181–1315 days posttransplant); all died. One ad-
ditional HTLV-1 negative recipient received a seropositive
liver.
What does this report add to current knowledge of the
approach to HTLV-1 seropositive potential recipients? Al-
though a ∼15% chance of developing a usually fatal dis-
ease (with additional patients possibly developing neuro-
logical or malignant disease with further follow-up) is by
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no means low, surprisingly the overall survival did not
differ between HTLV-1 positive and negative recipients.
Thus, with careful informed consent, pretransplant recip-
ient HTLV-1 infection should not be a contraindication to
SOT. The use of HTLV-1 positive donors into seronegative
recipients is more problematic. In low prevalence areas
like North America, this is rarely an issue and perhaps
only in extreme circumstances should HTLV-1 positive or-
gans be transplanted into seronegative recipients. In cir-
cumstances where HTLV-1 donor status is positive (e.g.
living donor), this report provides at least some additional
comfort in that the single mismatched patient did not de-
velop HTLV-1 disease after 6 years. This recipient remained
seronegative but nucleic acid positive emphasizing that
follow-up testing of seronegative recipients of seropos-
itive donors should include both serological and nucleic
acid testing. The elimination of the requirement for uni-
versal HTLV-1 deceased donor testing mandates that the
transplant community remains vigilant for cases of HAM
or ATL in recipients; this is likely the best way we have of
determining the outcome resulting from discontinuation of
donor testing.
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